Charles M. Winter - Jan 1, 2023 Form 3 Insider Report for Janux Therapeutics, Inc. (JANX)

Role
Chief Technical Officer
Signature
Maria Dobek, Attorney-in-Fact
Stock symbol
JANX
Transactions as of
Jan 1, 2023
Transactions value $
$0
Form type
3
Date filed
1/5/2023, 03:29 PM
Next filing
Jan 5, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding JANX Stock Option (right to buy) Jan 1, 2023 Common Stock 69.2K $4.21 Direct F1
holding JANX Stock Option (right to buy) Jan 1, 2023 Common Stock 70.5K $10.59 Direct F2
holding JANX Stock Option (right to buy) Jan 1, 2023 Common Stock 78K $20.24 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4th of the shares vested on March 10, 2022 and the balance of the shares vest thereafter in a series of 36 successive equal monthly installments. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
F2 1/4th of the shares vested on May 14, 2022 and the balance of the shares vest thereafter in a series of 36 successive equal monthly installments. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
F3 1/4th of the shares vested on January 1, 2023 and the balance of the shares vest thereafter in a series of 36 successive equal monthly installments.